Table 2.
Antiretroviral treatment used by patients with normal eGFR and with mildly-reduced eGFR.
| Variable | Global cohort | Normal eGFR | Mildly-reduced eGFR | p-value |
|---|---|---|---|---|
| Number of patients | 4337 | 3254 | 1083 | |
| Currently on ART, n (%) | 4199 (96.8) | 3132 (96.3) | 1067 (98.5) | <0.001 |
| Time under current ART regimen, yearsa | 1.3 (3.6) | 1.2 (3.5) | 1.5 (3.9) | <0.001 |
| Current ART regimen, n (%) | ||||
| No treatment | 138 (3.2) | 112 (3.7) | 16 (1.5) | |
| NNRTI-based | 2336 (53.9) | 1759 (54.1) | 577 (53.3) | 0.005 |
| PI-based | 136 (3.1) | 102 (3.1) | 34 (3.1) | |
| Boosted PI-based | 1257 (29.0) | 930 (28.6) | 327 (30.2) | |
| Integrase Inh-based | 439 (10.1) | 316 (9.7) | 123 (11.4) | |
| Other | 31 (0.7) | 25 (0.8) | 6 (0.6) | |
| Patients currently using, n (%) | ||||
| Tenofovir | 2825 (65.1) | 2169 (66.7) | 656 (60.6) | <0.001 |
| Indinavir | 0 | 0 | 0 | – |
| Atazanavir | 308 (7.1) | 237 (7.3) | 71 (6.6) | 0.419 |
| Darunavir | 808 (18.6) | 586 (18.0) | 222 (20.5) | 0.068 |
| Boosted PI | 1024 (23.6) | 755 (23.2) | 269 (24.8) | 0.272 |
| Patients having used, n (%) | ||||
| Lopinavir/ritonavir | 2010 (23.5) | 711 (21.9) | 309 (28.5) | <0.001 |
| Amprenavir | 44 (1.0) | 27 (0.8) | 17 (1.6) | 0.035 |
| Atazanavir | 923 (21.3) | 632 (19.4) | 291 (26.9) | <0.001 |
| Darunavir | 1069 (24.6) | 771 (23.7) | 298 (27.5) | 0.011 |
| Fosamprenavir | 182 (4.2) | 126 (3.9) | 56 (5.2) | 0.065 |
| Indinavir | 692 (16.0) | 429 (13.2) | 263 (24.3) | <0.001 |
| Nelfinavir | 462 (10.7) | 296 (9.1) | 166 (15.3) | <0.001 |
| Ritonavir | 1788 (41.2) | 1285 (39.5) | 503 (46.4) | <0.001 |
| Saquinavir | 431 (9.9) | 313 (9.6) | 118 (10.9) | 0.224 |
| Tenofovir | 3670 (84.6) | 2711 (83.3) | 959 (88.6) | <0.001 |
| Tipranavir | 58 (1.3) | 39 (1.2) | 19 (1.8) | 0.168 |
| Any PI | 2496 (57.6) | 1769 (54.4) | 727 (67.1) | <0.001 |
| Boosted PI | 2156 (49.7) | 1554 (47.8) | 602 (55.6) | <0.001 |
| Previous/current treatment with TEN, n (%) | 3670 (84.6) | 2711 (83.3) | 959 (88.6) | <0.001 |
| Previous/current treatment with boosted PI, n (%) | 2156 (49.7) | 1554 (47.8) | 602 (55.6) | <0.001 |
| Previous/current PI or boosted PI plus TEN, n (%) | 1865 (43.0) | 1313 (40.4) | 552 (51.0) | <0.001 |
| Previous/current PI or boosted PI without TEN, n (%) | 291 (6.7) | 241 (7.4) | 50 (4.6) | 0.001 |
| Previous/current NNRTI plus TEN, n (%) | 2144 (49.4) | 1615 (49.6) | 529 (48.8) | 0.654 |
| Previous/current NNRTI without TEN, n (%) | 192 (4.4) | 144 (4.4) | 48 (4.4) | 0.992 |
| Previous/current Integrase Inh plus TEN, n (%) | 381 (8.8) | 269 (8.3) | 112 (10.3) | 0.037 |
| Previous/current Integrase Inh without TEN, n (%) | 58 (1.3) | 47 (1.4) | 11 (1.0) | 0.287 |
| Duration of the treatment, yearsa | ||||
| Lopinavir/ritonavir | 2.40 (3.8) | 2.450 (3.8) | 2.30 (3.8) | 0.534 |
| Amprenavir | 1.50 (2.1) | 1.20 (2.4) | 1.75 (2.0) | 0.642 |
| Atazanavir | 2.90 (4.1) | 2.90 (4.1) | 3.00 (3.9) | 0.555 |
| Darunavir | 2.0 (2.3) | 1.90 (2.3) | 2.20 (2.6) | 0.242 |
| Fosamprenavir | 1.90 (3.8) | 1.80 (3.5) | 2.30 (4.7) | 0.358 |
| Indinavir | 1.70 (2.4) | 1.60 (1.9) | 1.90 (2.9) | 0.015 |
| Nelfinavir | 1.80 (2.5) | 2.00 (2.7) | 1.70 (2.1) | 0.114 |
| Ritonavir | 2.60 (4.2) | 2.40 (4.0) | 3.00 (4.7) | 0.002 |
| Saquinavir | 1.80 (2.8) | 2.00 (2.9) | 1.70 (2.3) | 0.264 |
| Tenofovir | 3.20 (4.4) | 3.00 (4.1) | 3.90 (4.9) | <0.001 |
| Tipranavir | 1.80 (2.9) | 2.00 (2.8) | 1.20 (2.9) | 0.716 |
| Any PI | 4.00 (5.8) | 3.90 (5.6) | 4.30 (6.2) | 0.008 |
| Boosted PI | 3.30 (5.0) | 3.10 (4.7) | 3.75 (5.2) | 0.004 |
a
Results expressed as median and interquartile range (IQR). Significant p < 0.05.
ART, antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; Inh, inhibitors; TEN, tenofovir disoproxil fumarate. All PIs were boosted with ritonavir.